Search

Search Constraints

You searched for: Author/Creator Letestu, Rémi

Search Results

1. Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study. Issue 13 (10th November 2021)

2. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO). Issue 5 (23rd October 2020)

3. Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia. Issue 2 (1st February 2016)

4. Evaluation of Paroxysmal Nocturnal Hemoglobinuria Screening by Flow Cytometry Through Multicentric Interlaboratory Comparison in Four Countries. Issue 6 (19th November 2015)

6. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Issue 9 (September 2019)

7. Prevalence, distribution and predictive value of XPO1 mutation in a real‐life chronic lymphocytic leukaemia cohort. (13th August 2020)

8. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Issue 2 (February 2018)

9. TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia. Issue 4 (1st February 2022)